BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 18278185)

  • 1. PAI-1 gene 4G/5G polymorphism, cytokine levels and their relations with metabolic parameters in obese children.
    Kinik ST; Ozbek N; Yuce M; Yazici AC; Verdi H; Ataç FB
    Thromb Haemost; 2008 Feb; 99(2):352-6. PubMed ID: 18278185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of plasminogen activator inhibitor-1 gene 4G/5G polymorphism on glucose and lipid metabolisms in Turkish obese children.
    Kinik ST; Ataç FB; Verdi H; Cetintaş S; Sahin FI; Ozbek N
    Clin Endocrinol (Oxf); 2005 May; 62(5):607-10. PubMed ID: 15853833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the 4G/5G polymorphism of PaI-1 gene promoter on PaI-1 levels in obese patients: influence of fat distribution and insulin-resistance.
    Sartori MT; Vettor R; De Pergola G; De Mitrio V; Saggiorato G; Della Mea P; Patrassi GM; Lombardi AM; Fabris R; Girolami A
    Thromb Haemost; 2001 Nov; 86(5):1161-9. PubMed ID: 11816701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma PAI-1 levels in obese children--effect of weight loss and influence of PAI-1 promoter 4G/5G genotype.
    Estellés A; Dalmau J; Falcó C; Berbel O; Castelló R; España F; Aznar J
    Thromb Haemost; 2001 Aug; 86(2):647-52. PubMed ID: 11522017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
    Stegnar M; Uhrin P; Peternel P; Mavri A; Salobir-Pajnic B; Stare J; Binder BR
    Thromb Haemost; 1998 May; 79(5):975-9. PubMed ID: 9609232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.
    Meigs JB; Dupuis J; Liu C; O'Donnell CJ; Fox CS; Kathiresan S; Gabriel SB; Larson MG; Yang Q; Herbert AG; Wilson PW; Feng D; Tofler GH; Cupples LA
    Obesity (Silver Spring); 2006 May; 14(5):753-8. PubMed ID: 16855181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [TNF-alpha and carbohydrate and lipid parameters in overweight and obese children].
    Goral J
    Ann Acad Med Stetin; 2008; 54(2):14-21. PubMed ID: 19374226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The common -675 4G/5G polymorphism in the plasminogen activator inhibitor -1 gene is strongly associated with obesity.
    Hoffstedt J; Andersson IL; Persson L; Isaksson B; Arner P
    Diabetologia; 2002 Apr; 45(4):584-7. PubMed ID: 12032637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.
    Matsubara Y; Murata M; Isshiki I; Watanabe R; Zama T; Watanabe G; Watanabe K; Ikeda Y
    Int J Hematol; 1999 Jan; 69(1):43-7. PubMed ID: 10641442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of gender and genetic variance in plasminogen activator inhibitor-1 secretion from human adipose tissue.
    van Harmelen V; Wahrenberg H; Eriksson P; Arner P
    Thromb Haemost; 2000 Feb; 83(2):304-8. PubMed ID: 10739390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the plasminogen activator inhibitor-1 gene a candidate gene predisposing to hypertension? Results from a population-based study in Spain.
    Martínez-Calatrava MJ; González-Sánchez JL; Zabena C; Martínez-Larrad MT; Luque-Otero M; Serrano-Ríos M
    J Hypertens; 2007 Apr; 25(4):773-7. PubMed ID: 17351368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
    Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS
    Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.
    Grancha S; Estellés A; Tormo G; Falco C; Gilabert J; España F; Cano A; Segui R; Aznar J
    Thromb Haemost; 1999 Apr; 81(4):516-21. PubMed ID: 10235431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. sP-selectin plasma levels in obesity: association with insulin resistance and related metabolic and prothrombotic factors.
    De Pergola G; Pannacciulli N; Coviello M; Scarangella A; Di Roma P; Caringella M; Venneri MT; Quaranta M; Giorgino R
    Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):227-32. PubMed ID: 17400434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between gene polymorphism of the PAI-1 promoter and myocardial infarction.
    Fu L; Jin H; Song K; Zhang C; Shen J; Huang Y
    Chin Med J (Engl); 2001 Mar; 114(3):266-9. PubMed ID: 11780311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjects.
    Pannacciulli N; De Mitrio V; Marino R; Giorgino R; De Pergola G
    Obes Res; 2002 Aug; 10(8):717-25. PubMed ID: 12181379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
    Castelló R; España F; Vázquez C; Fuster C; Almenar SM; Aznar J; Estellés A
    Thromb Res; 2006; 117(5):487-92. PubMed ID: 15907980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of proinflammatory cytokine gene polymorphisms for development of insulin resistance after renal transplantation.
    Gençtoy G; Kahraman S; Arici M; Altun B; Erdem Y; Bakkaloğlu M; Yasavul U; Turgan C
    Transplant Proc; 2006 Mar; 38(2):521-8. PubMed ID: 16549165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation.
    Mertens I; Ballaux D; Funahashi T; Matsuzawa Y; Van der Planken M; Verrijken A; Ruige JB; Van Gaal LF
    Thromb Haemost; 2005 Dec; 94(6):1190-5. PubMed ID: 16411393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde.
    Ye S; Green FR; Scarabin PY; Nicaud V; Bara L; Dawson SJ; Humphries SE; Evans A; Luc G; Cambou JP
    Thromb Haemost; 1995 Sep; 74(3):837-41. PubMed ID: 8571307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.